Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Myriad Genetics Inc MYGN

Healthcare Biotechnology
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has... see more

Recent & Breaking News (NDAQ:MYGN)

Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election

GlobeNewswire 1 day ago

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

GlobeNewswire June 11, 2024

Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen

GlobeNewswire June 4, 2024

Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

GlobeNewswire June 3, 2024

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting

GlobeNewswire May 23, 2024

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

GlobeNewswire May 16, 2024

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

GlobeNewswire May 7, 2024

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

GlobeNewswire May 7, 2024

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

GlobeNewswire April 30, 2024

Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

GlobeNewswire April 17, 2024

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

GlobeNewswire April 16, 2024

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

GlobeNewswire April 9, 2024

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

GlobeNewswire March 21, 2024

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

GlobeNewswire March 20, 2024

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

GlobeNewswire February 27, 2024

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

GlobeNewswire February 27, 2024

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

GlobeNewswire February 21, 2024

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women's Health

GlobeNewswire February 15, 2024

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

GlobeNewswire February 1, 2024

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

GlobeNewswire January 30, 2024